Pluim D - Search Results

1

Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL. Zamboni WC, et al. Among authors: pluim d. Clin Cancer Res. 2002 Sep;8(9):2992-9. Clin Cancer Res. 2002. PMID: 12231546

2

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Maliepaard M, et al. Among authors: pluim d. Cancer Res. 1999 Sep 15;59(18):4559-63. Cancer Res. 1999. PMID: 10493507

3

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

Pluim D, Maliepaard M, van Waardenburg RC, Beijnen JH, Schellens JH. Pluim D, et al. Anal Biochem. 1999 Nov 1;275(1):30-8. doi: 10.1006/abio.1999.4302. Anal Biochem. 1999. PMID: 10542106

4

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH. Maliepaard M, et al. Among authors: pluim d. Clin Cancer Res. 2001 Apr;7(4):935-41. Clin Cancer Res. 2001. PMID: 11309344

5

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.

Schoemaker NE, Herben VM, de Jong LA, van Waardenburg RC, Pluim D, ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Schoemaker NE, et al. Among authors: pluim d. Anticancer Drugs. 2002 Jan;13(1):87-91. doi: 10.1097/00001813-200201000-00010. Anticancer Drugs. 2002. PMID: 11914645

6

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.

van sen Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, Beijnen JH. van sen Bongard HJ, et al. Among authors: pluim d. Anticancer Drugs. 2002 Sep;13(8):807-14. doi: 10.1097/00001813-200209000-00004. Anticancer Drugs. 2002. PMID: 12394264

7

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH. Crul M, et al. Among authors: pluim d. Biochem Pharmacol. 2003 Jan 15;65(2):275-82. doi: 10.1016/s0006-2952(02)01508-3. Biochem Pharmacol. 2003. PMID: 12504803

8

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, Schellens JH. Bongard HJ, et al. Among authors: pluim d. Anticancer Drugs. 2003 Jul;14(6):405-10. doi: 10.1097/00001813-200307000-00003. Anticancer Drugs. 2003. PMID: 12853880

9

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Crul M, et al. Among authors: pluim d. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3526-33. Clin Cancer Res. 2003. PMID: 14506138 Clinical Trial.

10

Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model.

Brown DB, Ma MK, Battafarano RJ, Naidu S, Pluim D, Zamboni WC, McLeod HL. Brown DB, et al. Among authors: pluim d. Oncol Rep. 2004 Jan;11(1):237-43. Oncol Rep. 2004. PMID: 14654932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters